Get Live Data
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Netscientific Share Price
  4. Netscientific Share Regulatory News
  5. Director/PDMR Shareholding

Pin to quick picksNetscientific Regulatory News (NSCI)

Netscientific Information
  • There is currently no data for NSCI

Director/PDMR Shareholding

3 Oct 2023 16:12

RNS Number : 5716O
NetScientific PLC
03 October 2023
 

 

 

NetScientific plc

 

("NetScientific" or the "Company")

 

Director/PDMR Shareholding

 

NetScientific Plc (AIM: NSCI), the deeptech and life sciences VC investment group, announces that today, Mr Ed Hooper (Executive Director) purchased 20,000 ordinary shares in the capital of NetScientific Plc ("Ordinary Shares") through his Self-Invested Personal Pension.

 

Following such purchase, Ed Hooper is interested in 80,000 Ordinary Shares, representing 0.34 per cent. of the entire issued share capital of the Company.

 

The information below, set out in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

Name

Mr Edward Hooper

2

Reason for the notification

a)

Position/status

Director

b)

 

Initial notification /Amendment

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

NetScientific plc

b)

LEI

213800N5WD46G1Y7I458

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

NSCI 5p Ordinary Shares

 

  

GB00BN4R5Q82

b)

Nature of the transaction 

Purchase of Ordinary Shares into SIPP

c)

 

Price(s) and volume(s)

 

 

Price(s)

 

Volume(s)

Ă‚ÂŁ0.6290

Ă‚ÂŁ0.6320

Ă‚ÂŁ0.6394

10,000 shares

7,500 shares

2,500 shares

 

d)

 

Aggregated information

 - Aggregated volume

 

 - Price

 

 

 

Price

 

Volume

Ă‚ÂŁ0.6314

 

20,000 shares

e)

 

Date of the transaction

3 October 2023

f)

 

Place of the transaction

UK AIM

 

#Ă‚ #Ă‚ #

 

For more information, please contact:

NetScientific

Ilian Iliev, CEO

Via Belvedere Communications

 

 

WH Ireland (NOMAD, Financial Adviser and Broker)

 

Chris Fielding / Darshan Patel / Isaac Hooper

+44 (0)20 7220 1666

Belvedere Communications

John West / Llew Angus

 

+44 (0)20 3008 6867

 

About NetScientific

NetScientific plc (AIM: NSCI) is a deeptech and life sciences VC investment group with an international portfolio of innovative companies.

NetScientific identifies, invests in, and builds high growth companies in the UK and internationally. The company adds value through the proactive management of its portfolio, progressing to key value inflection points, and delivering investment returns through partial or full liquidity events.

NetScientific differentiates itself by employing a capital-efficient investment approach, making judicial use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital. The group secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a lean structure that can support a large portfolio.

NetScientific is headquartered in London, United Kingdom, and is admitted to trading on AIM, a market operated by the London Stock Exchange.

www.netscientific.net

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFSFFIDEDSEFS
234567891011
Date   Source Headline
6th Jan 20167:00 amRNSGlycotest Inc. appoints medical advisory board
4th Jan 20167:00 amRNSWANDA signs contract with HRS
16th Dec 20157:00 amRNSLawrence Cohen appointed as CEO of Glycotest Inc.
14th Dec 20157:00 amRNSAppointment of Gene Walther as Vortex CEO
3rd Dec 20157:00 amRNSProAxsis' ProteaseTagT research update
30th Nov 20157:00 amRNSProAxsis presents data to validate its immunoassay
16th Nov 20157:00 amRNSIssue of Equity
11th Nov 20157:00 amRNSHolding(s) in Company
10th Nov 20157:00 amRNSGrant of Options
6th Nov 201512:14 pmRNSResult of General Meeting
3rd Nov 20154:29 pmRNSHolding(s) in Company
21st Oct 20151:52 pmRNSPosting of Circular
1st Oct 20157:00 amRNSProposed Placing and Fund Raising to raise c.£20m
1st Oct 20157:00 amRNSHalf Yearly Report
18th Sep 20157:00 amRNSDivestment of Shareholding in Frontier BioSciences
16th Sep 20151:01 pmRNSHolding(s) in Company
15th Sep 20157:00 amRNSVortex BioSciences granted critical patent
9th Sep 20151:00 pmRNSSteve Curd appointed as CEO of Wanda
7th Aug 20157:00 amRNSDivestment of non-core assets to align portfolio
4th Aug 20157:00 amRNSProAxsis launches first-in-class ProteaseTag test
15th Jul 20157:00 amRNSKey patent granted for Glucosense's technology
22nd Jun 20151:19 pmRNSResults of Annual General Meeting
22nd Jun 20157:00 amRNSAGM Statement
5th Jun 20155:46 pmRNSNotification of Major Interest in Shares
5th Jun 20155:42 pmRNSNotification of Major Interest in Shares
5th Jun 20155:38 pmRNSNotification of Major Interest in Shares
5th Jun 20152:00 pmRNSNotification of Major Interest in Shares
5th Jun 20152:00 pmRNSNotification of Major Interest in Shares
28th May 201512:02 pmRNSPDS Biotechnology reports positive Phase I results
18th May 20157:00 amRNSNotice of AGM and Annual Report & Accounts
15th May 20157:00 amRNSCapital Markets Day
11th May 20157:00 amRNSDr. François R. Martelet appointed as CEO
7th May 20157:00 amRNSNetScientific invests in Neumitra
1st May 20157:00 amRNSNetScientific Forms New Digital Health Company
29th Apr 20159:00 amRNSNetScientific Capital Markets Day
1st Apr 20157:00 amRNSChange of Adviser
24th Mar 20157:00 amRNSSignificant Progress in core Portfolio Companies
20th Mar 20152:00 pmRNSNotice of Full Year Results
26th Feb 201510:07 amRNSAppointment of Non-Executive Director
16th Jan 20156:19 pmRNSDirectorate Change
7th Jan 20151:04 pmRNSNetScientific teams up with KU Leuven
7th Jan 20151:04 pmRNSNetScientific invests in DName-iT
15th Dec 20147:00 amRNSNetScientific invests in PDS Biotechnology
11th Dec 20147:00 amRNSNetScientific enters into alliance with Healthbox
8th Dec 20147:00 amRNSNetScientific invests in Breakout Labs' portfolio
17th Nov 20143:36 pmRNSHolding(s) in Company
17th Nov 20141:26 pmRNSHolding(s) in Company
3rd Oct 20147:00 amRNSSubsidiary, Glycotest collaboration with Oncimmune
23rd Sep 20147:00 amRNSHalf Yearly Report
17th Sep 20142:00 pmRNSNotice of Half Yearly Report
234567891011

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
FCM
First Class Metals PLC
LSE
-1.79%
FXPO
Ferrexpo
LSE
0.00%
EBOX
Tritax Eurobox
LSE
0.00%
CREO
Creo Medical
LSE
0.00%
NEO
Neo Energy Metals
LSE
2.33%
Trending
GST
GSTechnologies
LSE
4.04%
PREM
Premier African Minerals
LSE
-2.78%
QED
Quadrise
LSE
1.01%
CPI
Capita
LSE
3.62%
NTVO
Nativo Resources
LSE
4.55%